Targeting C‐type lectin receptors: a high‐carbohydrate diet for dendritic cells to improve cancer vaccines

Review of in vivo targeting of tumor antigens to lectin receptors on antigen‐presenting cells using antibodies or ligands may improve the antitumor efficacy of vaccines. There is a growing understanding of why certain patients do or do not respond to checkpoint inhibition therapy. This opens new opp...

Full description

Saved in:
Bibliographic Details
Published in:Journal of leukocyte biology Vol. 102; no. 4; pp. 1017 - 1034
Main Authors: Dinther, Dieke, Stolk, Dorian A., Ven, Rieneke, Kooyk, Yvette, Gruijl, Tanja D., Haan, Joke M. M.
Format: Journal Article
Language:English
Published: Bethesda, MD, USA Society for Leukocyte Biology 01.10.2017
Oxford University Press
Subjects:
Animals
Antibodies
Anticancer properties
Antigen (tumor-associated)
antigen presentation
Antigen-presenting cells
Antigens
Antitumor activity
Cancer
Cancer vaccines
Cancer Vaccines - genetics
Cancer Vaccines - immunology
Cancer Vaccines - therapeutic use
Carbohydrates
Cytotoxicity
Dendritic cells
Dendritic Cells - immunology
Humans
Immune checkpoint
Immune response
Immune system
Immunotherapy
Lectins
Lectins, C-Type - genetics
Lectins, C-Type - immunology
Lymphocytes
Lymphocytes T
Macrophages
Neoplasms - genetics
Neoplasms - immunology
Neoplasms - therapy
Priming
Receptors
Reviews
T cell receptors
T cells
T-Lymphocytes, Helper-Inducer - immunology
Vaccines
macrophages
antigen presentation
T cells
antigen presenting cells
ISSN:0741-5400, 1938-3673, 1938-3673
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Review of in vivo targeting of tumor antigens to lectin receptors on antigen‐presenting cells using antibodies or ligands may improve the antitumor efficacy of vaccines. There is a growing understanding of why certain patients do or do not respond to checkpoint inhibition therapy. This opens new opportunities to reconsider and redevelop vaccine strategies to prime an anticancer immune response. Combination of such vaccines with checkpoint inhibitors will both provide the fuel and release the brake for an efficient anticancer response. Here, we discuss vaccine strategies that use C‐type lectin receptor (CLR) targeting of APCs, such as dendritic cells and macrophages. APCs are a necessity for the priming of antigen‐specific cytotoxic and helper T cells. Because CLRs are natural carbohydrate‐recognition receptors highly expressed by multiple subsets of APCs and involved in uptake and processing of Ags for presentation, these receptors seem particularly interesting for targeting purposes.
Bibliography:These authors contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0741-5400
1938-3673
1938-3673
DOI:10.1189/jlb.5MR0217-059RR